| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mustafa Kılıçkap, Meral Kayıkçıoğlu, Lale Tokgözoğl. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Anatolian journal of cardiology. vol 25. issue 2. 2021-10-15. PMID:33583813. |
a systematic pubmed search was conducted for cv outcome studies of glp-1 receptor agonists and sglt-2 inhibitors with the main outcome of three-point major adverse cardiovascular events (mace), which is the composite of cv death, non-fatal myocardial infarction (mi), and non-fatal stroke. |
2021-10-15 |
2023-08-13 |
human |
| Huinan Zhang, Yunhan Liu, Liusiyuan Cheng, Xue Ma, Xiaoxing Lu. Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R. Brain research bulletin. vol 169. 2021-10-07. PMID:33197537. |
glucagon-like peptide-1 (glp-1) receptor (glp-1r) agonist exendin-4 (ex-4), a drug that has been used in the clinical treatment of type 2 diabetes mellitus, also confers a neuroprotective effect against stroke. |
2021-10-07 |
2023-08-13 |
mouse |
| Huinan Zhang, Yunhan Liu, Liusiyuan Cheng, Xue Ma, Xiaoxing Lu. Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R. Brain research bulletin. vol 169. 2021-10-07. PMID:33197537. |
although glp-1 analogs were reported to induce sustained insulin secretion and glucose tolerance improved after cessation of treatment, no study has revealed whether ex-4 exerts sustained neuroprotection against stroke and the underlying mechanism after treatment cessation. |
2021-10-07 |
2023-08-13 |
mouse |
| Tina K Thethi, Anika Bilal, Richard E Pratle. Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes spectrum : a publication of the American Diabetes Association. vol 34. issue 3. 2021-09-14. PMID:34511847. |
the glp-1 receptor agonists liraglutide, dulaglutide, and injectable semaglutide demonstrated a significant cv benefit in these trials and now have indications to reduce the risk of major adverse cv events, including cv death, myocardial infarction, and stroke in adult patients with type 2 diabetes and established cardiovascular disease or high cv risk (dulaglutide). |
2021-09-14 |
2023-08-13 |
Not clear |
| Shereen Nizari, Marina Basalay, Philippa Chapman, Nils Korte, Alla Korsak, Isabel N Christie, Shefeeq M Theparambil, Sean M Davidson, Frank Reimann, Stefan Trapp, Derek M Yellon, Alexander V Gourin. Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic research in cardiology. vol 116. issue 1. 2021-06-18. PMID:33942194. |
glucagon-like peptide-1 (glp-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. |
2021-06-18 |
2023-08-13 |
mouse |
| Shereen Nizari, Marina Basalay, Philippa Chapman, Nils Korte, Alla Korsak, Isabel N Christie, Shefeeq M Theparambil, Sean M Davidson, Frank Reimann, Stefan Trapp, Derek M Yellon, Alexander V Gourin. Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic research in cardiology. vol 116. issue 1. 2021-06-18. PMID:33942194. |
several preclinical studies demonstrated that the brain can be effectively protected against ischaemic stroke by two seemingly distinct treatments: remote ischaemic conditioning (ric), involving cycles of ischaemia/reperfusion applied to a peripheral organ or tissue, or by systemic administration of glucagon-like-peptide-1 (glp-1) receptor (glp-1r) agonists. |
2021-06-18 |
2023-08-13 |
mouse |
| Shereen Nizari, Marina Basalay, Philippa Chapman, Nils Korte, Alla Korsak, Isabel N Christie, Shefeeq M Theparambil, Sean M Davidson, Frank Reimann, Stefan Trapp, Derek M Yellon, Alexander V Gourin. Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic research in cardiology. vol 116. issue 1. 2021-06-18. PMID:33942194. |
in this study, we tested the hypothesis that glp-1 mediates neuroprotection induced by ric and investigated the effect of glp-1r activation on cerebral blood vessels, as a potential mechanism of glp-1-induced protection against ischaemic stroke. |
2021-06-18 |
2023-08-13 |
mouse |
| Ingrid Lovise Augestad, Doortje Dekens, Dimitra Karampatsi, Osama Elabi, Alexander Zabala, Hiranya Pintana, Martin Larsson, Thomas Nyström, Gesine Paul, Vladimer Darsalia, Cesare Patron. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British journal of pharmacology. 2021-06-17. PMID:33973246. |
glucagon-like peptide-1 (glp-1) receptor activation decreases stroke risk in people with type 2 diabetes (t2d), while animal studies have shown the efficacy of this strategy to counteract stroke-induced acute brain damage. |
2021-06-17 |
2023-08-13 |
mouse |
| Ingrid Lovise Augestad, Doortje Dekens, Dimitra Karampatsi, Osama Elabi, Alexander Zabala, Hiranya Pintana, Martin Larsson, Thomas Nyström, Gesine Paul, Vladimer Darsalia, Cesare Patron. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British journal of pharmacology. 2021-06-17. PMID:33973246. |
however, whether glp-1 receptor activation also improves recovery in the chronic phase after stroke is unknown. |
2021-06-17 |
2023-08-13 |
mouse |
| Jing Huang, Yunhan Liu, Liusiyuan Cheng, Jihong Li, Tangrui Zhang, Gang Zhao, Huinan Zhan. Glucagon-like peptide-1 cleavage product GLP-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes. European journal of pharmacology. vol 887. 2021-05-14. PMID:32949596. |
glucagon-like peptide-1 cleavage product glp-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes. |
2021-05-14 |
2023-08-13 |
mouse |
| Konark Malhotra, Aristeidis H Katsanos, Vaia Lambadiari, Nitin Goyal, Lina Palaiodimou, Maria Kosmidou, Christos Krogias, Andrei V Alexandrov, Georgios Tsivgouli. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. Journal of neurology. vol 267. issue 7. 2021-04-12. PMID:32246253. |
glp-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. |
2021-04-12 |
2023-08-13 |
Not clear |
| Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheun. Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. Cardiac failure review. vol 7. 2021-03-23. PMID:33747548. |
glp-1 receptor agonists have also showed some benefits, especially in stroke prevention. |
2021-03-23 |
2023-08-13 |
Not clear |
| Weiliang He, Haoyuan Wang, Congying Zhao, Xiaochao Tian, Litao Li, Hebo Wan. Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. Journal of cellular physiology. vol 235. issue 3. 2020-12-16. PMID:31535381. |
liraglutide (lg) is a new kind of long-acting analogue of glucagon-like peptide-1 (glp-1) and has potential protective effects in stroke. |
2020-12-16 |
2023-08-13 |
mouse |
| Elliot J Glotfelty, Thomas Delgado, Luis B Tovar-Y-Romo, Yu Luo, Barry Hoffer, Lars Olson, Tobias Karlsson, Mark P Mattson, Brandon Harvey, David Tweedie, Yazhou Li, Nigel H Grei. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. ACS pharmacology & translational science. vol 2. issue 2. 2020-10-01. PMID:31396586. |
a growing body of literature supports the use of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and glucagon (gcg) receptor (r) agonists, along with unimolecular combinations of these therapies, for their potent neurotrophic/neuroprotective activities across a variety of cellular and animal models of chronic neurodegenerative diseases (alzheimer's and parkinson's diseases) and acute cerebrovascular disorders (stroke). |
2020-10-01 |
2023-08-13 |
Not clear |
| David S H Bell, Edison Goncalve. Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies. Diabetes research and clinical practice. vol 164. 2020-08-06. PMID:32413380. |
utilizing pioglitazone and glp-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, dpp-4 and sglt-2 inhibitors have no effect. |
2020-08-06 |
2023-08-13 |
Not clear |
| Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Ernesto Germán Cardona Muñoz, Nana Pogosova, Peter J Raubenheimer, Jonathan E Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschie. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. The lancet. Diabetes & endocrinology. vol 8. issue 2. 2020-06-30. PMID:31924562. |
cardiovascular outcome trials have suggested that glucagon-like peptide 1 (glp-1) receptor agonists might reduce strokes. |
2020-06-30 |
2023-08-13 |
Not clear |
| Omar G Mustafa, Martin B Whyt. The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential. Diabetes/metabolism research and reviews. vol 35. issue 8. 2020-06-02. PMID:31141838. |
we searched the pubmed, embase, and google scholar databases, combining the term "glucagon-like peptide 1" or "glp-1" or "incretin" or "liraglutide" or "exenatide" or "lixisenatide" or "dulaglutide" or "albiglutide" and "inpatient" or "hospital" or "perioperative" or "postoperative" or "surgery" or "myocardial infarction" or "stroke" or "cerebrovascular disease" or "transient ischaemic attack" or "icu" or "critical care" or "critical illness" or "ccu" or "coronary care unit." |
2020-06-02 |
2023-08-13 |
human |
| Martin Larsson, Cesare Patrone, Mia von Euler, Jens J Holst, David Nathanso. GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. Cardiovascular diabetology. vol 18. issue 1. 2020-03-30. PMID:31307484. |
glucagon-like peptide-1 (glp-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. |
2020-03-30 |
2023-08-13 |
Not clear |
| Martin Larsson, Cesare Patrone, Mia von Euler, Jens J Holst, David Nathanso. GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. Cardiovascular diabetology. vol 18. issue 1. 2020-03-30. PMID:31307484. |
the prognostic value of endogenous levels of glp-1 in the recovery phase after stroke remains to be elucidated. |
2020-03-30 |
2023-08-13 |
Not clear |
| Martin Larsson, Cesare Patrone, Mia von Euler, Jens J Holst, David Nathanso. GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. Cardiovascular diabetology. vol 18. issue 1. 2020-03-30. PMID:31307484. |
the aim of the study was to investigate the potential association between glp-1 levels and functional outcome after stroke and to determine whether glp-1 is altered in the acute phase of stroke compared to 3 months post stroke and to healthy controls. |
2020-03-30 |
2023-08-13 |
Not clear |